Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Brought to you by

Urovant launches and gets rights to Merck's Phase III vibegron

Executive Summary

Roivant Sciences Ltd. launched Urovant Sciences, which has licensed a late-stage overactive bladder candidate from Merck & Co. Inc. as its first project.

Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • Includes Royalty or Profit Split Information
    • R&D and Marketing (Licensing)
    • Reverse Licensing

Related Companies

UsernamePublicRestriction

Register